Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) FCF Margin (2016 - 2025)

Historic FCF Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 7047.5%.

  • Northwest Biotherapeutics' FCF Margin fell 46920400.0% to 7047.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 5427.64%, marking a year-over-year decrease of 19722500.0%. This contributed to the annual value of 4199.06% for FY2024, which is 12449200.0% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported FCF Margin of 7047.5% as of Q3 2025, which was down 46920400.0% from 5337.4% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' FCF Margin ranged from a high of 1428.64% in Q1 2023 and a low of 8770.13% during Q4 2024
  • For the 5-year period, Northwest Biotherapeutics' FCF Margin averaged around 4202.89%, with its median value being 3407.0% (2023).
  • As far as peak fluctuations go, Northwest Biotherapeutics' FCF Margin skyrocketed by 2000000000bps in 2021, and later plummeted by -51856800bps in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' FCF Margin (Quarter) stood at 2772.57% in 2021, then soared by 33bps to 1844.05% in 2022, then tumbled by -112bps to 3904.72% in 2023, then plummeted by -125bps to 8770.13% in 2024, then increased by 20bps to 7047.5% in 2025.
  • Its FCF Margin stands at 7047.5% for Q3 2025, versus 5337.4% for Q2 2025 and 2536.27% for Q1 2025.